Beam Therapeutics reported a net loss of $112.7 million, or $1.10 per share, for the third quarter of 2025, compared to a net loss of $96.7 million, or $1.17 per share, for the same period in 2024. Research and development expenses reached $109.8 million, up from $94.3 million in the third quarter of 2024. General and administrative expenses were $26.7 million, slightly higher than $26.5 million a year earlier. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $1.1 billion, up from $850.7 million on December 31, 2024. The company expects its cash reserves to fund operations into 2028. During the period, Beam continued dose exploration in the BEAM-302 Phase 1/2 study in alpha-1 antitrypsin deficiency, is advancing the BEAM-301 trial in glycogen storage disease Ia, and plans to present updated BEACON Phase 1/2 trial data for BEAM-101 in sickle cell disease at the upcoming American Society of Hematology Annual Meeting. The first subject was also dosed in a healthy volunteer trial of BEAM-103, an anti-CD117 monoclonal antibody.